Leveraging the power of machine learning and DNA sequencing technology to combat the drug resistance crisis
Leveraging the power of machine learning and DNA sequencing technology to combat the drug resistance crisis
Antibiotic resistance is predicted to be the global leading cause of death by 2050, taking 10 million lives annually. New solutions are direly needed now. At Informuta, we believe in conserving our current market-approved antibiotics and learning how to better use them to improve treatment outcomes. To do this, we are leveraging machine learning and genomics data to develop RESISENSE, our breakthrough, patent-pending diagnostic that can directly tell clinicians the best drugs to use on a patient-by-patient basis.
We focus on giving hospitals and clinicians the most information on infections to aid in clinical decision-making, with the goal of enabling targeted treatment and precision-based care. Our technology allow us to be the most comprehensive and robust diagnostic for drug-resistant infections than any other on the market. We are also the first ever that can predict drug resistance in patients before it even happens, helping to improve outcomes, decrease incidence, and decrease cost of resistant infections.
Our first multi-center clinical trial is set to begin November 2024, with the anticipated launch of our first product in late 2026. If you are interested in participating as a clinical trial site, please contact us for more information.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
